29.2 C
New York
Saturday, June 19, 2021

Rubius Therapeutics Inc (RUBY) stock is Surging, and here is the reason WHY?

Rubius Therapeutics Inc (RUBY) Stock soared on the last day of the week, and it gained 49.12% in the after-hours on Friday, March 12, 2021. The reason behind their soaring price is the announcement made by RUBY Stock.


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



What is an important announcement?

Rubius Therapeutics Inc (RUBY) announced on March 12, 2021, that its goings to do a webcast on Monday, March 15, 2021, to share this initial data from the ongoing Phase 1/2 trial of RTX-240 in patients with advanced solid tumors

RUBY will host a conference call and webcast with a slide presentation at 8:00 a.m. EDT on Monday, March 15, to discuss this update. The link to the conference call’s webcast will be posted on the Investors & Media section of the RUBY’s website.

RUBY’s financial news

On February 23, 2021, Ruby reported fourth-quarter and full-year 2020 financial results.

Fourth Quarter 2020 highlights

  • Rubius Therapeutics suffered a net loss of $40.5 million or $0.50 per common share for the fourth quarter of 2020.
  • RUBY invested $25.6 million in the research and development program while spending $14.1 million in G&A expenses.

Full-year 2020 highlights

  • Rubius Therapeutics suffered a net loss of $167.7 million or $2.08 per common share, compared to $163.5 million or $2.08 per common share for the full year 2019.
  • RUBY R&D expenses for the full year 2020 was $116.1 million related to its novel RED PLATFORM
  • $50.3 million were spent on G&A expenses during the twelve months of 2020
  • cash, cash equivalents and investments were $176.3 million by the end of 2020.

About the Company

Rubius Therapeutics was founded in 2013, and its headquarter is in Massachusetts, United States. Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company was recently named among the Top Places to Work in Massachusetts by the Boston Globe.

The CEO and president of Rubius Therapeutics are Pablo Cagnoni. He has worked as an oncologist and pharmaceutical executive. He played an essential role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®. He has extensive experience of more than 20 years in the medical field and has worked at different executive positions in may prominent companies worldwide.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.